Cagrilintide: Complete Research Guide (2026)

Amylin is the hormone that gets overlooked in metabolic research while GLP-1 gets all the attention. Cagrilintide is designed to change that. It’s a long-acting amylin analog that activates the amylin receptor system, a fundamentally different pathway from GLP-1, and the clinical data shows it can produce meaningful weight and metabolic effects both alone and in combination.

The combination data is particularly interesting. When researchers paired cagrilintide with a GLP-1 analog, the effects appeared additive rather than redundant. That suggests these are genuinely separate pathways to appetite modulation, not two versions of the same mechanism.

Key Takeaways

• Cagrilintide (AM833) is a long-acting acylated amylin analog that activates amylin receptors (AMYR/CTR)
• Amylin is co-secreted with insulin from pancreatic beta cells; it’s part of the normal post-meal hormonal response
• Acts as a non-selective amylin receptor agonist through the calcitonin G protein-coupled receptor (CTR)
• Separate mechanism from GLP-1 receptor agonists, with documented additive appetite reduction in combination
• Multiple published clinical trials showing weight effects as monotherapy and with semaglutide
• Long-acting formulation achieved through acylation, enabling less frequent dosing in research settings

What Is Cagrilintide?

Cagrilintide, also designated AM833, is a novel long-acting amylin analog. It was engineered as a non-selective agonist at amylin receptors, which are formed by the combination of calcitonin receptors with receptor activity-modifying proteins (RAMPs).

Amylin itself is a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells in response to meals. It complements insulin’s post-meal role: where insulin manages glucose uptake in peripheral tissues, amylin signals to the brain that food has arrived, contributes to slowing gastric emptying, and suppresses glucagon secretion.

The natural amylin hormone has too short a half-life for pharmaceutical research use. Cagrilintide solves this through acylation, the attachment of a fatty acid chain that allows the molecule to bind to albumin in the bloodstream, dramatically extending its effective duration. This same approach is used for other long-acting peptide analogs in diabetes research.

For researchers studying metabolic hormone signaling, research-grade Cagrilintide provides a stable, long-acting tool for examining amylin receptor pathway activation.

How Does Cagrilintide Work?

Amylin Receptor System

Amylin receptors (AMYRs) are complexes formed when calcitonin receptors (CTRs) combine with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). The different RAMP combinations produce receptors with slightly different binding profiles. Cagrilintide acts as a non-selective agonist across this receptor family.

The brain areas most relevant to amylin’s appetite effects are in the brainstem, particularly the area postrema, which lacks the blood-brain barrier and is accessible to circulating hormones. Amylin receptor activation in these areas contributes to satiety signaling and meal termination.

Mechanism Distinct from GLP-1

This is the key research point about cagrilintide: it achieves appetite suppression and metabolic effects through a pathway that doesn’t overlap significantly with GLP-1 receptor agonism. GLP-1 receptors and amylin receptors are different proteins expressed in different cell populations, using different intracellular signaling cascades.

The implication is that combining amylin receptor agonism with GLP-1 receptor agonism could produce additive effects that neither can achieve alone at the same dose. The clinical research tested exactly this hypothesis.

Glucagon Suppression

Part of amylin’s normal post-meal role is suppressing glucagon, which prevents excessive post-meal blood sugar elevation (glucagon raises blood sugar; suppressing it post-meal keeps glucose management cleaner). Cagrilintide, as an amylin receptor agonist, preserves this glucagon-suppressing mechanism.

What Does the Research Show?

Journal of Medicinal Chemistry Development Study (2021, ACS)

The foundational cagrilintide paper was published in the Journal of Medicinal Chemistry in 2021, documenting the compound’s development as a long-acting amylin analog. The paper described the acylation approach that achieved extended half-life and documented the initial clinical results showing significant weight reduction in trials conducted alone and in combination with semaglutide (a GLP-1 analog).

The combination finding was the headline result: when cagrilintide was added to semaglutide in the research protocol, weight reduction was greater than with either compound alone, consistent with the additive pathway hypothesis.

2023 Clinical Review (PubMed)

A 2023 publication reviewed cagrilintide’s development and mechanism, emphasizing the additive effect of amylin-analog and GLP-1 receptor agonist combination. The review framed cagrilintide as targeting multiple pathophysiological pathways in metabolic disease, positioning the combination approach as the more complete metabolic intervention.

This review also addressed the scientific rationale for why separate mechanisms produce additive rather than overlapping effects, providing a more detailed mechanistic picture of the receptor-level biology.

2022 Amylin-as-Obesity-Treatment Review (PMC)

A 2022 PMC review on “Amylin as a Future Obesity Treatment” provided broader context for cagrilintide’s mechanism, describing the amylin receptor system’s role in energy homeostasis. It confirmed cagrilintide’s designation as an attractive novel treatment approach in obesity research because of its distinct mechanism and the documented weight effects.

The review noted that amylin’s central signaling effects are complementary to, rather than redundant with, the incretin pathway targeted by GLP-1 analogs. This mechanistic separation is what makes the combination approach scientifically coherent.

Combination Trial Data

Clinical trials pairing cagrilintide with semaglutide have produced some of the more impressive weight reduction data in the metabolic peptide research space. The additive effect hypothesis has been supported across multiple study designs, with the combination consistently producing greater effects than the monotherapy arms.

The combination data also showed improvements in cardiometabolic markers beyond weight, including triglycerides and blood pressure in some studies.

Purity, Testing, and Quality Considerations

Cagrilintide’s acylation, the fatty acid attachment that enables long-acting behavior, adds analytical complexity compared to simple peptide compounds. The correct molecular weight of the acylated compound must be confirmed by mass spectrometry. An unacrylated or incorrectly acylated product might show peptide sequence identity but would have fundamentally different pharmacokinetic properties.

HPLC purity at 98%+ is standard. The acyl chain should be present and confirmed in the analytical data. Third-party COA documentation with full method disclosure is the appropriate standard.

Third-party tested Cagrilintide from Concordia Research Chems includes full analytical documentation covering both peptide sequence verification and acylation confirmation.

Related Compounds

Cagrilintide’s research context is defined by its relationship to other metabolic pathway compounds.

GLP-3 R targets the GLP-1, GIP, and glucagon receptor systems, a completely different set of targets from cagrilintide’s amylin receptor focus. The research question of whether amylin receptor activation and GLP-1/GIP/glucagon triple agonism produce additive effects is an open one. The GLP-3 R guide covers the triple-agonist mechanism in detail.

MOTS-c takes a mitochondrial approach to metabolic regulation, functioning as an exercise mimetic rather than through hormonal receptor signaling. The contrast with cagrilintide illustrates how different the research approaches to metabolic intervention can be. See the MOTS-c guide.

Where the Research Is Heading

Cagrilintide is in active clinical development. The combination data with GLP-1 analogs has generated enough interest that phase 3 programs are examining the combination as a potential treatment approach for metabolic disease.

The fundamental research question that will define cagrilintide’s future in the literature is whether the additive effects hold at scale, and what the optimal combination ratios look like across different metabolic phenotypes. Some patients may be better amylin responders, others better GLP-1 responders, and understanding that heterogeneity will shape how the combination is used in clinical research.

The amylin field has been waiting for a long-acting analog with this kind of clinical data for some time. Cagrilintide may be the compound that finally establishes amylin receptor agonism as a first-class target in metabolic research rather than a secondary consideration.

Concordia Research Chems carries research-grade Cagrilintide for laboratory research. The metabolic peptide field is moving quickly, and amylin receptor agonism is one of the more exciting mechanistic directions emerging.